The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.

Autor:	Butler J; Cardiology Division, Stony Brook University, Stony Brook, NY, USA., Hamo CE; Cardiology Division, Stony Brook University, Stony Brook, NY, USA., Filippatos G; National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece., Pocock SJ; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK., Bernstein RA; Department of Neurology, Feinberg School of Medicine of Northwestern University, Chicago, IL, USA., Brueckmann M; Boehringer Ingelheim Pharmaceuticals Inc., Ingelheim, Germany.; Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany., Cheung AK; Division of Nephrology and Hypertension, University of Utah, Salt Lake City, UT, USA., George JT; Boehringer Ingelheim Pharmaceuticals Inc., Ingelheim, Germany.; Warwick Medical School, University of Warwick, UK., Green JB; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA., Januzzi JL; Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA., Kaul S; Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Lam CSP; National Heart Centre Singapore and Duke-National University of Singapore, Singapore., Lip GYH; Institute of Cardiovascular Science, University of Birmingham, UK, and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Marx N; Department of Internal Medicine I, Cardiology, RWTH Aachen University, Aachen, Germany., McCullough PA; Baylor Heart and Vascular Institute, Dallas, TX, USA., Mehta CR; Harvard School of Public Health, Boston, MA, USA., Ponikowski P; Medical University, Clinical Military Hospital, Wroclaw, Poland., Rosenstock J; Dallas Diabetes Research Center at Medical City and University of Texas Southwestern Medical Center, Dallas, TX, USA., Sattar N; BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK., Salsali A; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA., Scirica BM; TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Shah SJ; Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Tsutsui H; Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan., Verma S; Division of Cardiac Surgery, Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of St. Michael's Hospital Departments of Surgery, and Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada., Wanner C; Division of Nephrology, Department of Medicine, University Hospital, Wurzburg, Germany., Woerle HJ; Boehringer Ingelheim Pharmaceuticals Inc., Ingelheim, Germany., Zannad F; Inserm CIC 1433, U 1116, Université de Lorraine and CHU, Nancy, France., Anker SD; Department of Cardiology and Pneumology, University Medical Centre Göttingen, Göttingen, Germany.; Division of Cardiology and Metabolism, Department of Cardiology (CVK).; Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Germany.; Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) Berlin, Germany.; Charité Universitätsmedizin Berlin, Germany.
Jazyk:	angličtina
Zdroj:	European journal of heart failure [Eur J Heart Fail] 2017 Nov; Vol. 19 (11), pp. 1390-1400. Date of Electronic Publication: 2017 Aug 24.
DOI:	10.1002/ejhf.933
Abstrakt:	Heart failure (HF) and type 2 diabetes mellitus (T2DM) are both growing public health concerns contributing to major medical and economic burdens to society. T2DM increases the risk of HF, frequently occurs concomitantly with HF, and worsens the prognosis of HF. Several anti-hyperglycaemic medications have been associated with a concern for worse HF outcomes. More recently, the results of the EMPA-REG OUTCOME trial showed that the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin was associated with a pronounced and precocious 38% reduction in cardiovascular mortality in subjects with T2DM and established cardiovascular disease [Correction added on 8 September 2017, after first online publication: "32%" in the previous sentence was corrected to "38%"]. These benefits were more related to a reduction in incident HF events rather than to ischaemic vascular endpoints. Several mechanisms have been put forward to explain these benefits, which also raise the possibility of using these drugs as therapies not only in the prevention of HF, but also for the treatment of patients with established HF regardless of the presence or absence of diabetes. Several large trials are currently exploring this postulate. (© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF